Sera Prognostics, Inc. (NASDAQ:SERA) Insider Robert Gardner Harrison Sells 14,209 Shares

Sera Prognostics, Inc. (NASDAQ:SERA - Get Free Report) insider Robert Gardner Harrison sold 14,209 shares of the stock in a transaction that occurred on Friday, January 10th. The stock was sold at an average price of $7.39, for a total value of $105,004.51. Following the sale, the insider now directly owns 116,837 shares of the company's stock, valued at approximately $863,425.43. The trade was a 10.84 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through the SEC website.

Robert Gardner Harrison also recently made the following trade(s):

• On Monday, January 13th, Robert Gardner Harrison sold 2,264 shares of Sera Prognostics stock. The shares were sold at an average price of $6.47, for a total transaction of $14,648.08.

Sera Prognostics Stock Up 0.6 %

Shares of NASDAQ:SERA traded up $0.04 during midday trading on Tuesday, reaching $6.37. 134,610 shares of the company were exchanged, compared to its average volume of 143,614. The firm has a market cap of $215.13 million, a PE ratio of -6.43 and a beta of 0.86. Sera Prognostics, Inc. has a fifty-two week low of $4.98 and a fifty-two week high of $12.35. The stock has a fifty day simple moving average of $7.44 and a two-hundred day simple moving average of $7.31.

Sera Prognostics (NASDAQ:SERA - Get Free Report) last released its quarterly earnings results on Wednesday, November 6th. The company reported ($0.24) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.22) by ($0.02). The business had revenue of $0.03 million during the quarter, compared to analysts' expectations of $0.09 million. During the same quarter last year, the company earned ($0.23) earnings per share. As a group, analysts forecast that Sera Prognostics, Inc. will post -0.96 earnings per share for the current year.

Institutional Investors Weigh In On Sera Prognostics

A number of hedge funds and other institutional investors have recently bought and sold shares of the company. Quest Partners LLC boosted its position in Sera Prognostics by 533.5% during the 3rd quarter. Quest Partners LLC now owns 6,430 shares of the company's stock worth $50,000 after acquiring an additional 5,415 shares during the last quarter. The Manufacturers Life Insurance Company acquired a new position in Sera Prognostics during the second quarter worth $68,000. SG Americas Securities LLC bought a new position in Sera Prognostics in the third quarter valued at $78,000. Prime Capital Investment Advisors LLC bought a new position in Sera Prognostics in the third quarter valued at $104,000. Finally, Jane Street Group LLC increased its stake in Sera Prognostics by 24.8% in the 3rd quarter. Jane Street Group LLC now owns 14,225 shares of the company's stock valued at $111,000 after buying an additional 2,826 shares during the last quarter. Institutional investors and hedge funds own 54.64% of the company's stock.

Sera Prognostics Company Profile

Sera Prognostics, Inc, a women's health diagnostic company, discovers, develops, and commercializes biomarker tests for improving pregnancy outcomes in the United States. The company develops PreTRM test, a blood-based biomarker test to predict the risk of spontaneous preterm birth in singleton pregnancies.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.